This article first appeared on GuruFocus .
-
Product Revenue:Q3 2026 product revenue of $57.7 million, up 10% year-over-year; first nine months of 2026 up 14% to $168.8 million.
-
North American Product Revenue:Increased 12% year-over-year in Q3; accounted for just over two-thirds of quarterly product revenue.
-
EMEA Product Revenue:Increased 5% year-over-year as reported; unfavorable FX negatively impacted reported growth by approximately 2%.
-
IFC Product Revenue:$5.6 million in Q3 2026 versus $3.9 million in Q3 2025; 90% of IFC sales shipped in kit form during the quarter.
-
Platelet Volume:North American platelet kit and calculated platelet doses increased 5% year-over-year.
-
IFC Sales Volume:Increased 7% sequentially on a dose-equivalent basis.
-
Full-Year 2026 Product Revenue Guidance:Reaffirmed range of $229 million to $231 million, including IFC sales of $23 million to $25 million.
-
Government Contract Revenue:Declined to $6.3 million from $7.5 million in Q3 2025; not included in revenue guidance or adjusted EBITDA.
-
Product Gross Margin:52.4% in Q3 2026 versus 53.4% in Q3 2025 and 51.4% in Q2 2026.
-
Total Operating Expenses:$36.2 million versus $34.4 million in Q3 2025, up 5% against 10% product revenue growth.
-
R&D Expenses:Down 10% year-over-year; government-funded R&D accounted for 31% of total R&D spend.
-
GAAP Net Loss:Under $1 million attributable to Cerus in Q3 2026, approaching breakeven.
-
Adjusted EBITDA:$5.7 million versus $5.0 million in Q3 2025; 10th consecutive quarter of positive adjusted EBITDA.
-
Cash Flow from Operations:$3 million generated in Q3 2026.
-
Cash and Investments:Cash equivalents and short-term investments of $57.1 million as of September 30, 2026, up close to $1 million from June 30.
Release Date: November 02, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Worldwide product revenue increased 10% year-over-year to $57.7 million, with North American sales up 12%.
-
Achieved 10th consecutive quarter of positive adjusted EBITDA at $5.7 million and generated $3 million in positive cash flow from operations.
-
Positive top-line results from Phase 3 REDIS trial for red blood cell pathogen reduction, meeting primary efficacy endpoint and showing no statistically significant difference in safety.
-
IFC franchise showed strong growth with 90% of sales in kit form, improving gross margins and expanding hospital reach through blood center distribution.
-
International placements of INT200 illuminator exceeded expectations, contributing to growth and setting foundation for further kit penetration.
Negative Points
-
Geopolitical conflicts in the Middle East and Russia, along with a strengthened US dollar, created near-term headwinds in EMEA, with product revenue growth of only 5% year-over-year.
-
CE-mark clearance for red blood cell technology now expected in late 2027, delayed as additional REDIS data is included in the submission.
-
FDA PMA platelet submission for INT200 received preliminary feedback requiring additional data, creating uncertainty in approval timing.
-
Product gross margin declined to 52.4% from 53.4% in the prior year due to foreign exchange and inflation headwinds.
-
Government contract revenue declined to $6.3 million from $7.5 million year-over-year due to the conclusion of the FDA contract and wind-down of the BARDA 2016 contract.
Q & A Highlights
Q: What are the next steps with the FDA for the Gen. 1 red blood cell (RBC) system following the positive Phase 3 ReCePi results, and is there any update on the Gen. 2 system? A: CEO Vivek Jayaraman stated that the next steps involve completing the full data analysis to support submitting a clinical study report to the FDA as part of the approval process, as well as submitting it for publication and presentation. Once the report is finalized and submitted, the company will meet with the agency to better understand the timing and pathway forward. In parallel, Cerus is working on the Gen. 2 system, which is expected to be the main go-to-market system, with more specifics to be shared as they enter 2027.
Q: Can you provide some color on the underlying health of the international markets, particularly regarding the Russia-Ukraine dynamic and potential distributor choppiness? A: CEO Vivek Jayaraman explained that while geopolitical tensions are impacting the business, the company believes these headwinds are transient. Cerus's market share and leadership position in these regions remain strong, and they are working closely with distributor partners to ensure continuity of supply. He also noted that the strengthening US dollar remains a headwind, but the company is focused on controlling what it can, such as serving customers well and continuing clinical education, while seeing strong adoption of the INT200 in international markets.
Q: What were the key drivers behind the impressive 80% volume growth in the IFC business during the third quarter? A: CEO Vivek Jayaraman attributed the growth to the nationwide agreement with Blood Centers of America (BCA), which represents over 50% of blood product distributions in the US. The agreement allows Cerus to leverage BCA's resource-sharing model and sales network to expand its reach into US hospitals. Additionally, increased customer depth, peer-to-peer dialogue at conferences, and the transition to a kit model, which allows for quicker account penetration and better economics, all contributed to the strong performance.
Q: What is the expected timeline for the full data analysis of the Phase 3 ReCePi study, and have the secondary endpoints read out yet? A: CEO Vivek Jayaraman agreed that a first-half 2027 timeline for the full data analysis is a reasonable expectation, noting that the information is embargoed to ensure the best possible audience for publication and podium presence. He also confirmed that the company remains blinded to the secondary endpoints, as only the top-line results from the primary efficacy and safety endpoints were reported.
Q: How should investors think about the potential for the Gen. 2 device to be incorporated into the FDA process? A: CEO Vivek Jayaraman clarified that the company is applying for approval with the Gen. 1 system first. Once past design freeze, all work on the Gen. 2 system will be submitted for approval as a follow-on to the Gen. 1 device approval.
Q: Can you provide an update on the evaluation of the INTERCEPT system in Germany? A: CEO Vivek Jayaraman noted that the INITIATE post-market clinical trial in partnership with the German Red Cross continues to enroll at a healthy clip with positive customer feedback. Separately, the PEI is evaluating a potential countrywide health policy for platelet safety, similar to the FDA's guidance on bacterial safety. Cerus believes that if this policy is finalized, it would be favorable for the adoption of Intercept in the German market, which is seen as a meaningful growth opportunity for the rest of the decade.
Q: How was this year's AABB experience different given the BCA agreement, and are you seeing new opportunities as a result? A: CEO Vivek Jayaraman said the AABB conference provided tangible evidence that the BCA agreement is bearing fruit. He noted that peer-to-peer marketing is a highly effective tool, and a number of new BCA centers have come on board for both IFC and platelet production and distribution. Since BCA members account for about 50% of blood products distributed nationwide, this represents the largest opportunity for growth in both platelet and IFC adoption.
Q: What are the critical steps needed in the marketplace for the red blood cell product to become a big product following potential FDA approval? A: CEO Vivek Jayaraman emphasized that the company's acute focus is on finalizing and analyzing the clinical study data and submitting it to the FDA and for publication. He believes the strong body of clinical evidence, combined with over a decade of experience with pathogen reduction in other blood components, creates underlying market desire. The planned limited market release in Europe post-CE mark will generate real-world experience that will be informative and educational for US commercialization.
Q: What are the key puts and takes for product revenue in 2027, particularly regarding international business and IFC growth? A: CEO Vivek Jayaraman declined to provide formal 2027 guidance but noted that the US business was the acute source of strength in Q3, driven by IFC and continued share capture in the core platelet business. While acknowledging transient international headwinds, he expressed long-term confidence in the international business due to continued adoption of the INT200 and strategic market access work. He believes the diverse portfolio allows the company to navigate acute headwinds while the US business strengthens.
Q: Where do you think IFC market share can go over the next few years, given it was last estimated at about 10%? A: CEO Vivek Jayaraman stated that Cerus believes IFC has the ability to become the standard of care, which is the company's aspiration across all product categories. Given the product's performance, clinical enthusiasm, and impact on patients, he believes it can be a life-saving intervention and a material growth driver for the company for years to come.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
